Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial

(2022) Sabina Kersting et al.   Lancet Haematology

Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study

(2021) Husam Abdel-Qadir et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model for chronic lymphocytic leukemia

(2021) Arnon P. Kater et al.   Blood Advances

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

(2021) Thomas E Lew et al.   Blood Advances

First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study

(2021) Tahla Munir et al.   BLOOD

Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively

(2021) Carol Moreno et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Changes in Bcl-2 members in response to ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

(2020) Marco Vincent Haselager et al.   BLOOD

Real‐World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

(2020) Kathrine Aarup et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

(2020) Carsten Utoft Niemann et al.   BLOOD

Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model

(2020) Inhye E. Ahn et al.   JOURNAL OF CLINICAL ONCOLOGY

Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations

(2020) Mark-David Levin et al.   BMJ Open

Ibrutinib and Venetoclax for First-Line Treatment of CLL

(2019) Nitin Jain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

(2019) Peter Hillmen et al.   JOURNAL OF CLINICAL ONCOLOGY

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

(2018) Michael Hallek et al.   BLOOD

Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy

(2018) Jan A. Burger et al.   Nature Reviews Clinical Oncology

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

(2018) John F. Seymour et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia

(2018) Piers Blombery et al.   Cancer Discovery

Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition

(2017) E Slinger et al.   LEUKEMIA

BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199

(2016) K. Bojarczuk et al.   BLOOD

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

(2016) M. A. Anderson et al.   BLOOD

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience

(2015) Luc-Matthieu Fornecker et al.   AMERICAN JOURNAL OF HEMATOLOGY

Ibrutinib inhibits BCR and NF- B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

(2014) S. E. M. Herman et al.   BLOOD

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch

(2014) Farrukh T. Awan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells

(2014) Lesley A. Mathews Griner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL

(2012) A C Rawstron et al.   LEUKEMIA

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY